Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Vanguard U.S. Momentum Factor ETF (NY:VFMO)

205.80 -0.81 (-0.39%)
Streaming Delayed Price Updated: 2:47 PM EST, Feb 19, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Vanguard U.S. Momentum Factor ETF

< Previous 1 2 3 Next >
Jefferies CEO Claims Bank Was ‘Defrauded’ By Bankrupt Auto Supplier First Brands Group ↗
Via Stocktwits
Topics Bankruptcy Supply Chain
Jeff Bezos Reportedly Says People Should Be Thrilled About AI: ‘Don’t See How Anybody Can Be Discouraged Who Is Alive’ ↗
Via Stocktwits
Eli Lilly Says Verzenio Reduced Risk of Death In Late-Stage Trial In Some Breast Cancer Patients ↗
Via Stocktwits
Boston Scientific To Acquire Privately-Held Pain Solutions Developer Nalu Medical For About $533M ↗
Via Stocktwits
Sana Biotech Stock Jumps A Whopping 35% After Eric Jackson Calls It ‘Next 100-Bagger Platform’ ↗
Via Stocktwits
News headline image
FDA Approves Alzheimer’s Test Developed By Roche In Collaboration With Eli Lilly ↗
The blood-based test is aimed at aiding the initial assessment for Alzheimer’s disease and other causes of cognitive decline in the primary-care setting in patients aged 55 and older. 
Via Stocktwits
AnaptysBio Stock Gets A Price Target Hike After Announcing Plan To Separate Royalty, Biopharma Businesses – Check Out The New Level ↗
Via Stocktwits
Eli Lilly Terminates Study Of Bimagrumab In Obesity ↗
Via Stocktwits
Eli Lilly Announces Plan To Construct New $6.5B Facility In Texas ↗
Via Stocktwits
Scholar Rock In Spotlight After FDA Refuses To Approve Muscular Atrophy Treatment Over Third-Party Manufacturing Facility Issues ↗
Via Stocktwits
News headline image
Apollo Global Eyes Spanish Market With Focus On Energy, Data Centers, And Infrastructure: Report ↗
According to a Bloomberg News report, these sectors are where Apollo will be looking for players with the “biggest needs.” 
Via Stocktwits
Topics Government
KalVista Pharmaceuticals’ Hereditary Angioedema Drug Approved In EU, Switzerland: Retail Sees Stock Rallying To $22 In A Year ↗
Via Stocktwits
Uber Inks Partnership With Flytrex For Drone Delivery In US: Retail Sees Stock ‘Going Higher For Longer’ ↗
Via Stocktwits
News headline image
Roivant Stock Rises After Drug Achieves Goals In Late-Stage Study: Retail Sees Further Rally To $17 ↗
Once-daily oral Brepocitinib 30 mg demonstrated clinically meaningful and statistically significant improvement compared to placebo on the primary endpoint and all key secondary endpoints in the study,... 
Via Stocktwits
News headline image
Duolingo Stock Dips After Citigroup Lowers Price Target – Here’s What The Analyst Said About Duocon Event ↗
Citigroup maintained a ‘Buy’ rating and noted that Duolingo's product announcements this year had a lower profile relative to the past. 
Via Stocktwits
Topics Artificial Intelligence
Eli Lilly To Set Up $5B Facility In Virginia – More Details Inside ↗
Via Stocktwits
Ralph Lauren Unveils Three-Year Outlook – Here Are The Key Points ↗
Via Stocktwits
Caleres Draws ‘Less Risk’ Rating From Telsey, Retail Chatter Surges 700% ↗
Via Stocktwits
Iovance Stock Rises 4% On Health Canada Approval For Cancer Immunotherapy: Retail Thinks ‘Patience Will Pay Off’ ↗
Via Stocktwits
News headline image
Dave & Buster’s Sees Wall Street Downgrades, Yet Retail Sentiment Red-Hot ↗
UBS said that while Dave & Buster’s was still in the early stages of a turnaround, with macro pressure remaining elevated and visibility limited, an eventual return to consistently positive same-store... 
Via Stocktwits
News headline image
Summit Therapeutics Gets A $40 Price Target As Guggenheim Says It Likes Stock At $24, Like It Did At $3 ↗
The price target of $40 represents an upside of 70% from the stock’s closing price on Wednesday. 
Via Stocktwits
News headline image
Agios Pharma Stock Slumped 15% Today But Company Remains Top Pick For This Analyst – Find Out More ↗
While the FDA was originally expected to decide on the company’s application for Pyrukynd in treating thalassemia by September 7, its decision is now expected by December 7. 
Via Stocktwits
News headline image
Zymeworks Stock Tanks Over 17% After Cancer Drug Candidate Update ↗
The company was testing the drug in an early-stage trial in patients with ovarian cancer and non-small cell lung cancer. 
Via Stocktwits
Lyft Has A ‘Steady Path Forward’ According To UBS: Retail Thinks Stock Is Undervalued ↗
Via Stocktwits
Ardelyx Stock Soars On Price Target Hikes After Upbeat Q2 Report: Retail Sees More Revisions Coming ↗
Via Stocktwits
Vertex Stock Sinks 12% As Pipeline Setbacks Trigger Wall Street Skepticism: But Retail Sees Opportunity ↗
Via Stocktwits
Oscar Health Now Expects Loss From Operations Of $200M To $300M In 2025: Here’s What Retail Thinks About The Stock Price ↗
Via Stocktwits
News headline image
HC Wainwright Doubles Price Target On Insmed After Brinsupri Approval: Retail Expects Stock To Hit $150 By End Of Week ↗
The analyst sees Insmed as "poised to join the ranks" of Roche's Genentech and Pfizer's Seagen as companies that have successfully deployed the "pipeline-in-a-pill" strategy. 
Via Stocktwits
News headline image
Hims & Hers Announces Plans To Expand Into Canada As Novo Nordisk’s Weight Loss Drug Patent Expires ↗
The telehealth company stated that its entry to Canada will come as generic semaglutide hits the market for the first time. 
Via Stocktwits
Topics Intellectual Property
News headline image
Rhythm Pharma Shares Soar After Experimental Drug Yields Weight Reduction In Brain-Damage Related Obesity ↗
Rhythm now plans to seek input from U.S. and EU regulatory authorities on a late-stage trial design to advance Bivamelagon in acquired hypothalamic obesity. 
Via Stocktwits
Topics Government
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.